All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2024-06-03.
From the record
KORU Medical Systems, Inc.'s filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2024-06-03) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+13.1% a year over 8 filed years; profitable in 2 of 8.
From the record
KORU Medical Systems, Inc.'s 8 filed years say what it did: revenue went from $17 million in fiscal 2018 to $41 million in fiscal 2025, up 13.1% a year; it rose in 6 of 7 years; the deepest fall was 3% from fiscal 2020 to fiscal 2021; net income was positive in 2 of 8 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 7.7/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: KORU Medical Systems, Inc.'s shareholder treatment is put at 7.7 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 23% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -15%: lost 15¢ per shareholder dollar. Leverage 40%: owes 40¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, KORU Medical Systems, Inc. lost about 15 cents for every dollar of shareholders' money, and gross profitability: its products earned about 91 cents per dollar of everything the company owns. Leverage: it owed about 40 cents per dollar of assets, and net share issuance: its share count grew 0.8% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 49% of 109 in its family; net margin -6.4%.
From the record
KORU Medical Systems, Inc.'s standing among 109 graded names in its industry family: revenue of $41 million in fiscal 2025 ranks in the bottom 38% by size; a net margin of -6.4% ranks in the top 36%; revenue growth of 13.8% a year over the last 3 filed years ranks in the top 50% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 46% of 91 in its family for leadership; chief executive since 2021.
From the record
KORU Medical Systems, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Tharby, Linda M (Chief Executive Officer, as filed), filing under that title since 2021-04-14, 5.6 years (top 43% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 4.5 years (bottom 35%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 30%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 43% of 104 in its family for room to expand.
From the record
KORU Medical Systems, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $9 million against no long-term debt tagged leaves 31.5% of its assets as net cash, top 27% of its family; cash from operations less capital spending is -1.1% of revenue (top 44%); a gross margin of 62.3% (top 47%); research spending of 10.7% of revenue (bottom 46%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 46% of 105 in its family for growth drivers.
From the record
KORU Medical Systems, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 13.8% a year over the last three filed years against 13.1% over all 8, speeding up (top 32% of its family); the newest year grew 22.3% (top 29%); research spending grew -4% a year (bottom 25%); capital spending grew -30.4% a year (bottom 18%) (its annual reports). KORU Medical Systems, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 24% of 88 in its family for expectations against reality.
From the record
KORU Medical Systems, Inc.'s newest year against its own record: revenue of $41 million in fiscal 2025 came in 11.3% above the $37 million its prior three years' pace pointed to (top 16% of its family); net income of $3 million against a prior three-year average of $9 million (top 23%); a net margin of -6.4% against -32.4% before (top 32%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made